Cargando…
B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171743/ http://dx.doi.org/10.1097/01.HS9.0000936124.56965.24 |
| _version_ | 1785039487720488960 |
|---|---|
| author | Rodríguez-Otero, P. Ailawadhi, S. Arnulf, B. Patel, K. Cavo, M. Nooka, A.K. Manier, S. Callander, N. Costa, L.J. Vij, R. Bahlis, N.J. Moreau, P. Solomon, S.R. Delforge, M. Berdeja, J. Truppel-Hartmann, A. Yang, Z. Favre-Kontula, L. Wu, F. Piasecki, J. Cook, M. Giralt, S. |
| author_facet | Rodríguez-Otero, P. Ailawadhi, S. Arnulf, B. Patel, K. Cavo, M. Nooka, A.K. Manier, S. Callander, N. Costa, L.J. Vij, R. Bahlis, N.J. Moreau, P. Solomon, S.R. Delforge, M. Berdeja, J. Truppel-Hartmann, A. Yang, Z. Favre-Kontula, L. Wu, F. Piasecki, J. Cook, M. Giralt, S. |
| author_sort | Rodríguez-Otero, P. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171743 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101717432023-05-11 B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL Rodríguez-Otero, P. Ailawadhi, S. Arnulf, B. Patel, K. Cavo, M. Nooka, A.K. Manier, S. Callander, N. Costa, L.J. Vij, R. Bahlis, N.J. Moreau, P. Solomon, S.R. Delforge, M. Berdeja, J. Truppel-Hartmann, A. Yang, Z. Favre-Kontula, L. Wu, F. Piasecki, J. Cook, M. Giralt, S. Hemasphere Best Abstracts - Oral Presentations Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171743/ http://dx.doi.org/10.1097/01.HS9.0000936124.56965.24 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Best Abstracts - Oral Presentations Rodríguez-Otero, P. Ailawadhi, S. Arnulf, B. Patel, K. Cavo, M. Nooka, A.K. Manier, S. Callander, N. Costa, L.J. Vij, R. Bahlis, N.J. Moreau, P. Solomon, S.R. Delforge, M. Berdeja, J. Truppel-Hartmann, A. Yang, Z. Favre-Kontula, L. Wu, F. Piasecki, J. Cook, M. Giralt, S. B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL |
| title | B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL |
| title_full | B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL |
| title_fullStr | B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL |
| title_full_unstemmed | B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL |
| title_short | B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL |
| title_sort | b08 idecabtagene vicleucel versus standard regimens in patients with triple-class–exposed relapsed and refractory multiple myeloma: karmma-3 a phase 3 randomized controlled trial |
| topic | Best Abstracts - Oral Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171743/ http://dx.doi.org/10.1097/01.HS9.0000936124.56965.24 |
| work_keys_str_mv | AT rodriguezoterop b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT ailawadhis b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT arnulfb b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT patelk b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT cavom b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT nookaak b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT maniers b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT callandern b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT costalj b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT vijr b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT bahlisnj b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT moreaup b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT solomonsr b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT delforgem b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT berdejaj b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT truppelhartmanna b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT yangz b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT favrekontulal b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT wuf b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT piaseckij b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT cookm b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial AT giralts b08idecabtagenevicleucelversusstandardregimensinpatientswithtripleclassexposedrelapsedandrefractorymultiplemyelomakarmma3aphase3randomizedcontrolledtrial |